As the population of people living with HIV ages, atherosclerotic cardiovascular disease (ASCVD) has become an increasing cause of morbidity and mortality. Traditional cardiovascular risk factors are common among those with HIV. In addition, some antiretroviral therapy (ART) regimens contribute to conditions such as hyperlipidemia and insulin resistance. However, inflammation is increasingly recognized as a key contributor to ASCVD. HIV infection induces immune activation and inflammation through several mechanisms. Co-infections such as hepatitis C and cytomegalovirus along with HIV itself likely initiate immune activation and inflammation. Translocation of bacterial products across a compromised epithelial barrier as a result of HIV infection is another mechanism by which the immune system is activated. In this article we summarize the current understanding of drivers of immune activation and inflammation among those with HIV and the contribution of each to ASCVD.
FrenchALGawelSHHershowR. Trends in mortality and causes of death among women with HIV in the United States: a 10-year study. J Acquir Immune Defic Syndr2009; 51: 399–406.
2.
TriantVALeeHHadiganC. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab2007; 92: 2506–2512.
3.
Reinsch N, Neuhaus K, Esser S, et al. Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study. Eur J Prevent Cardiol 2012; 19: 267–74.
4.
WormSWSabinCWeberR. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis2010; 201: 318–330.
5.
GrinspoonSKGrunfeldCKotlerDP. State of the science conference initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS Executive Summary. Circulation2008; 118: 198–210.
6.
DolanSEHadiganCKillileaKM. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr2005; 39: 44–54.
7.
El-SadrWMMullinCMGilbertC. Effects of HIV disease on LIID, glucose and insulin levels: results form a large antiretroviral-naive cohort. HIV Med2005; 6: 114–121.
8.
TorrianiFJKomarowLParkerRA. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy. J Am Coll Cardiol2008; 52: 569–576.
9.
PaiJKPischonTMaJ. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med2004; 351: 2599–2610.
10.
BermudezEARifaiNBuringJE. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Throm Vasc Biol2002; 22: 1668–1673.
11.
RidkerPMHennekensCHBuringJE. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med2000; 342: 836–843.
12.
GalkinaELeyK. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol2009; 27: 165–197.
13.
RidkerPMRifaiNStampferMJ. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation2000; 101: 1767–1772.
14.
LibbyP. Inflammation in atherosclerosis. Nature2002; 420: 868–874.
15.
FisherSDMillerTLLipshultzSE. Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis. Atherosclerosis2006; 185: 1–11.
16.
PapagnoLSpinaCAMarchantA. Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol2004; 2(2): E20–E20.
17.
RobbinsGKSpritzlerJGChanES. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis2009; 48: 350–361.
18.
KlineERSutliffRL. The roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunction. J Investig Med2008; 56: 752–769.
19.
RenZYaoQChenC. HIV-1 envelope glycoprotein 120 increases intercellular adhesion molecule-1 expression by human endothelial cells. Lab Invest2002; 82: 245–255.
20.
BuonaguroLBarillariGChangHK. Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J Virol1992; 66: 7159–7167.
21.
ScalaGRuoccoMRAmbrosinoC. The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. J Exp Med1994; 179: 961–971.
22.
RieckmannPPoliGFoxCH. Recombinant gp120 specifically enhances tumor necrosis factor-alpha production and Ig secretion in B lymphocytes from HIV-infected individuals but not from seronegative donors. J Immunol1991; 147: 2922–2927.
23.
LeeCLiuQHTomkowiczB. Macrophage activation through CCR5- and CXCR4-mediated gp120-elicited signaling pathways. J Leukoc Biol2003; 74: 676–682.
24.
SwinglerSMannAJacqueJ. HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat Med1999; 5: 997–998.
25.
El-SadrWMLundgrenJDNeatonJD. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med2006; 355: 2283–2296.
26.
NeuhausJJacobsDRJrBakerJV. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis2010; 201: 1788–1795.
27.
KullerLHTracyRBellosoW. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med2008; 5(10): e203–e203.
28.
HsuePYHuntPWSinclairE. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T‐cell responses. AIDS2006; 20: 2275–2283.
29.
TorreDPuglieseA. Interleukin-18 and cardiovascular disease in HIV-1 infection: a partner in crime?AIDS Rev2010; 12: 31–39.
30.
HsuePYHuntPWSchnellA. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS2009; 23: 1059–1067.
31.
KaplanRCKingsleyLAGangeSJ. Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS2008; 22: 1615–1624.
32.
LewdenCCheneGMorlatP. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach the same mortality as the general population. J Acquir Immune Defic Syndr2007; 46: 72–77.
33.
AppayVSauceD. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol2008; 214: 231–241.
34.
KaplanRSinclairELandayL. T-cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis2011; 203: 452–463.
35.
AltfeldMAddoMMShankarappaR. Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol2003; 77: 7330–7340.
36.
HeydtmannMAdamsDH. Chemokines in the immunopathogenesis of hepatitis C infection. Hepatology2009; 49: 676–687.
37.
YonkersNLSiegSRodriguezBAnthonyDD. Reduced naive CD4 T cell numbers and impaired induction of CD27 in response to T cell receptor stimulation reflect a state of immune activation in chronic hepatitis C virus infection. J Infect Dis2011; 203: 635–645.
38.
KovacsAAl-HarthiLChristensenS. CD8(+) T cell activation in women co-infected with human immunodeficiency virus type 1 and hepatitis C virus. J Infect Dis2008; 197: 1402–1407.
39.
ButtAAXiaoqiangWBudoffM. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis2009; 49: 225–232.
40.
BedimoRWestfallAOMugaveroM. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med2010; 11: 462–468.
41.
TienPCSchneiderMFColeSR. Association of hepatitis C virus and HIV infection with subclinical atherosclerosis in the women's interagency HIV study. AIDS2009; 23: 1781–1784.
42.
BoddiMAbbateRChelliniB. Hepatitis C virus RNA localization in human carotid plaques. J Clin Virol2010; 47: 72–75.
43.
ClarkeLMDuerrAFeldmanJ. Factors associated with cytomegalovirus infection among human immunodeficiency virus type 1-seronegative and -seropositive women from an urban minority community. J Infect Dis1996; 173: 77–82.
44.
LunardiCBasonCCorrocherR. Induction of endothelial cell damage by hCMV molecular mimicry. Trends Immunol2005; 26: 19–24.
45.
MelnickJLAdamEDeBakeyME. Possible role of cytomegalovirus in atherogenesis. JAMA1990; 263: 2204–2207.
46.
GrattanMTMoreno-CabralCEStarnesVA. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA1989; 261: 3561–3566.
47.
ZhouYFLeonMBWaclawiwMA. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med1996; 335: 624–630.
48.
RobertsETHaanMNDowdJB. Cytomegalovirus antibody levels, inflammation, and mortality among elderly Latinos over 9 years of follow-up. Am J Epidemiol2010; 172: 363–371.
49.
AlmanzarGSchwaigerSJeneweinB. Long-term cytomegalovirus infection leads to significant changes in the composition of the CD8+ T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons. J Virol2005; 79: 3675–3683.
50.
GuadalupeMReayESankaranS. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol2003; 77: 11708–11717.
51.
SankaranSGeorgeMDReayE. Rapid onset of intestinal epithelial barrier dysfunction in primary human immunodeficiency virus infection is driven by an imbalance between immune response and mucosal repair and regeneration. J Virol2008; 82: 538–545.
52.
KumarHKawaiTAkiraS. Toll-like receptors and innate immunity. Biochem Biophys Res Comm2009; 388: 621–625.
53.
BrenchleyJMPriceDASchackerTW. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med2006; 12: 1365–1371.
54.
PapasavvasEPistilliMReynoldsG. Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients. AIDS2009; 23: 369–375.
55.
JiangWLedermanMMHuntP. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis2009; 199: 1177–1185.
56.
MarchettiGBellistriGMBorghiE. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS2008; 22: 2035–2038.
57.
Merlini E, Bai F, Suardi E, et al. Microbial translocation-induced immune activation associates to atherosclerosis in cART-treated HIV+ patients. In: Programs and Abstracts of the 18th Conference on Retroviruses and Opportunistic Infections (CROI), Hynes Convention Center, Boston, MA 27, February–2 March 2011. Vot 18, Abs 309.
58.
FunderburgNTMayneESiegSF. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood2010; 115: 161–167.
